Assessment of metabolic perturbations associated with exposure to phthalates among pregnant African American women

• Authors: Xiaoyue Zhang, Emory University; Dana Barr, Emory University; Anne Dunlop, Emory University; Parinya Panuwet, Emory University; Jeremy Sarnat, Emory University; Grace E Lee, Emory University; Youran Tan, Emory University; Elizabeth Corwin, Emory University; Dean Jones, Emory University; P Ryan, Emory University; Donghai Liang, Emory University
• Journal Title: SCIENCE OF THE TOTAL ENVIRONMENT
• Volume: Volume 818
• Publisher: ELSEVIER | 2022-03-04, Pages 151689-151689
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1016/j.scitotenv.2021.151689
• Subjects: Health Sciences, Nursing; Environmental Sciences
• Keywords: Science & Technology; Life Sciences & Biomedicine; Environmental Sciences; Environmental Sciences & Ecology; Phthalates; Urinary phthalate metabolites; High-resolution metabolomics; Metabolic perturbations; HIGH-RESOLUTION METABOLOMICS; OXIDATIVE STRESS; INFLAMMATORY RESPONSE; BILIRUBIN; BIOMARKERS; HEALTH; RISK; ANTIOXIDANT; INDUCTION; CAFFEINE

Abstract

Background: Phthalates have been linked with numerous harmful health effects. Limited data are available on the molecular mechanism underlying phthalate toxicity on human health. In this study, we measured urinary phthalate metabolites and used high-resolution metabolomics (HRM) to identify biological perturbations associated with phthalate exposures among pregnant African American (AA) women, who are disproportionately exposed to high phthalates levels. Methods: We used untargeted HRM profiling to characterize serum samples collected during early (8–14 weeks gestation) and late (24–30 weeks gestation) pregnancy from 73 participants from the Atlanta AA Maternal-Child cohort. We measured eight urinary phthalate metabolites in early and late pregnancy, including Monoethyl phthalate (MEP), Mono(2-ethlyhexyl) phthalate (MEHP), and Mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), to assess maternal exposures to phthalates. Metabolite and metabolic pathway perturbation were evaluated using an untargeted HRM workflow. Results: Geometric mean creatinine-adjusted levels of urinary MEP, MEHP, and MEHHP were 67.3, 1.4, and 4.1 μg/g creatinine, respectively, with MEP and MEHP higher than the mean levels of non-Hispanic blacks in the general US population (2015–2016). There were 73 and 1435 metabolic features significantly associated with at least one phthalate metabolite during early and late pregnancy (p < 0.005), respectively. Pathway enrichment analysis revealed perturbations in four inflammation- and oxidative-stress-related pathways associated with phthalate metabolite levels during both early and late pregnancy, including glycerophospholipid, urea cycle, arginine, and tyrosine metabolism. We confirmed 10 metabolites with level-1 evidence, which are associated with urinary phthalates, including thyroxine and thiamine, which were negatively associated with MEP, as well as tyramine and phenethylamine, which were positively associated with MEHP and MEHHP. Conclusion: Our results demonstrated that urinary phthalate levels were associated with perturbations in biological pathways connected with inflammation, oxidative stress, and endocrine disruption. The findings support future targeted investigations on molecular mechanisms underlying the impact of maternal phthalates exposure on adverse health outcomes.